TARA
Protara Therapeutics Inc
3.30$
-2.1%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -52.6% | +11.1% | +90.0% | +115.8% | +20.3% | -22.3% | +142.6% | -29.7% | -40.3% | +112.0% | +37.5% | -2.6% | +9.0% | |
| – | – | – | +371.5% | +54.5% | -100.0% | +370,318.4% | -72.5% | +933.5% | +6.3% | -35.5% | -8.9% | -32.3% | -7.2% | |
| – | – | – | +414.1% | +18.6% | -7.2% | +11.5% | -72.3% | +933.5% | +24.1% | +219.9% | – | – | – | |
| – | – | -69.8% | +200.0% | +295.4% | +241.2% | -235.4% | – | – | -15.1% | +0.9% | -867.9% | – | -173.4% | |
| – | -85.1% | +410.0% | +288.2% | +36.9% | -87.1% | +240.0% | -86.6% | +5,425.0% | -32.6% | -79.9% | -62.5% | +40.0% | +49.2% | |
| – | -63.1% | -557.8% | -9.2% | – | -180.8% | – | -86.5% | +14.1% | -3,563.6% | – | +255.2% | -63.9% | -828.2% | |
| – | – | – | -99.8% | +27.6% | +10,981.3% | -87.0% | – | – | -100.2% | -60.5% | +1.1% | – | – | |
| – | – | – | – | – | – | +0.0% | +0.0% | +0.0% | -100.0% | – | – | – | – | |
| – | – | +1,930.3% | -99.8% | +27.6% | +10,981.3% | -87.0% | -83.2% | +37,780.2% | -100.1% | -60.5% | +1.1% | – | -40.9% | |
| – | – | – | -143.6% | – | – | – | – | – | -178.7% | – | – | +697.0% | -191.8% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.